Electrocardiographic Safety of Repeated Monthly Dihydroartemisinin-Piperaquine as a Candidate for Mass Drug Administration | Zendy

Pere Millat-Martínez | Zendy; Rhoda Ila | Zendy; Moses Laman | Zendy; Leanne J. Robinson | Zendy; Harin Karunajeewa | Zendy; Haina Abel | Zendy; Kevin Pulai | Zendy; Sergi Sanz | Zendy; Laurens Manning | Zendy; Brioni R. Moore | Zendy; Quique Bassat | Zendy; Natàlia Casamitjana | Zendy

Open Access

Electrocardiographic Safety of Repeated Monthly Dihydroartemisinin-Piperaquine as a Candidate for Mass Drug Administration

Author(s) -

Pere Millat-Martínez,

Rhoda Ila,

Moses Laman,

Leanne J. Robinson,

Harin Karunajeewa,

Haina Abel,

Kevin Pulai,

Sergi Sanz,

Laurens Manning,

Brioni R. Moore,

Quique Bassat,

Natàlia Casamitjana

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01153-18

Subject(s) - piperaquine , dihydroartemisinin , mass drug administration , pharmacology , medicine , malaria , drug , food and drug administration , artemisinin , plasmodium falciparum , immunology , environmental health , population

Mass drug administration (MDA) of sequential rounds of antimalarial drugs is being considered for use as a tool for malaria elimination. As an effective and long-acting antimalarial, dihydroartemisinin-piperaquine (DHA-PQP) appears to be suitable as a candidate for MDA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research